Rocket Pharmaceuticals (RCKT) Share-based Compensation (2014 - 2026)

Rocket Pharmaceuticals has reported Share-based Compensation for 13 years, with the latest figure at $8.5 million in Q1 2026.

• Quarterly Share-based Compensation fell 17.79% year-over-year to $8.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.2 million (down 19.95% YoY) and the FY2025 annual result came in at $37.8 million, down 35.38% from the prior year.
• Share-based Compensation grew to $8.5 million in Q1 2026 per RCKT's latest filing, from $6.1 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $11.3 million in Q2 2024 and troughed at $6.1 million in Q4 2025.
• A 5-year average of $9.4 million and a median of $9.9 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation soared 42.19% in 2023, then plunged 44.88% in 2025.
• Over 5 years, Share-based Compensation stood at $9.7 million in 2022, then increased by 2.45% to $9.9 million in 2023, then advanced by 11.66% to $11.1 million in 2024, then sank by 44.88% to $6.1 million in 2025, then soared by 38.96% to $8.5 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $8.5 million, $6.1 million, and $9.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.